本周,热点较多。首先是审评审批方面,共有4个1类新药国内获批上市,分别是上海医药的苹果酸司妥吉仑片、中国生物制药的库莫西利胶囊、健康元的玛帕西沙韦以及诺诚健华的佐来曲替尼片;其次是研发方面,阿斯利康收购的双靶CAR-T药物AZD0120ORR达100%;再次是交易及投融资方面,药友制药与辉瑞达成GLP-1药物YP05002独家合作与许可协议,总交易额超20亿美元;最后是上市方面,君赛生物向港交所...
Source Link本周,热点较多。首先是审评审批方面,共有4个1类新药国内获批上市,分别是上海医药的苹果酸司妥吉仑片、中国生物制药的库莫西利胶囊、健康元的玛帕西沙韦以及诺诚健华的佐来曲替尼片;其次是研发方面,阿斯利康收购的双靶CAR-T药物AZD0120ORR达100%;再次是交易及投融资方面,药友制药与辉瑞达成GLP-1药物YP05002独家合作与许可协议,总交易额超20亿美元;最后是上市方面,君赛生物向港交所...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.